Cempra Pharmaceuticals, Inc.

Baxter International Inc.

Vanda Pharmaceuticals Inc.

Other

Baxter Healthcare Sa

Ponce De Leon Health Designated Activity Company

David Eugene Pereira

Prabhavathi Fernandes

Ton That Hai

Deanna J Nelson

Wade Aumiller

Raymond Dagger

Douglas L Looker

David L Foster

Kenneth E Burhop

Michael P Doyle

Keshav Deo

Geoffrey F Lee

Izydor Z Apostol

Stephen P Trimble

Christopher B Glascock

Douglas D Lemon

Jane P Richards

Eric A Brucker

Michael R Schick

Ton-That Hai

Manish Kanchanbhai Patel

James C Hartman

Edwin G Moore

Susan L Trimbo

Timothy N Estep

Patrick F Jonas

Sara Wu

Francis Ros&eacute;

Bruce Rowe

Xavier Leverve

Prabhavathi B Fernandes

Sumana Konar

Methods and processes for preparing calcium salts of alpha-ketoglutarate are described herein.

Process of making calcium alpha-ketoglutarate

Pharmaceutical compositions adapted for the parenteral administration, including intravenous administration, of triazole containing macrolide antibiotics, and methods for their use in the treatment of bacterial, protozoal, and other infections are described herein.

Parenteral formulations for administering macrolide antibiotics

Described herein are processes for the preparation of compounds of formula (I): and pharmaceutically acceptable salts, solvates, and hydrates thereof.

Process for the preparation of macrolide antibacterial agents

Described herein are compounds and pharmaceutical compositions useful for treating inflammatory diseases.

Compounds and methods for treating inflammatory diseases

Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating diseases caused at least in party by resistant bacteria.

Methods for treating resistant diseases using triazole containing macrolides

The invention described herein pertains to a novel macrolide antibacterial agent of formula (I): A-L-Q, as defined herein, and pharmaceutically acceptable salts, solvates, and hydrates thereof. Inter alia, the new macrolide antibacterial agent is active against a number of bacterial species, including resistant species.

Hydrogen bond forming fluoro ketolides for treating diseases

The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side chain.

Convergent processes for preparing macrolide antibacterial agents

The invention described herein pertains to processes for the preparation of macrolide antibacterial agents. In particular, the invention pertains to processes for preparing macrolides and ketolides from erythromycin A.

Process for preparing triazole-containing ketolide antibiotics

New crystalline forms of macrolide compounds, and pharmaceutical compositions thereof, are described herein. In addition, processes for preparing the crystalline forms are described herein.

Crystalline forms of a macrolide, and uses therefor

Triazole-containing macrolide and ketolide antibiotics, therapeutic compositions containing them and methods of use for treating diseases caused by one or more resistant organisms are described.

Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran,deprotonated 1,2-cyclohexanediamino-N,N'-bis(3,5-di-t-butyl-salicylidene) and RuCl(p-cymene)].

Ruthenium (II) catalysts for use in stereoselective cyclopropanations

Chiral ruthenium catalysts comprising salen and alkenyl ligands are provided for stereoselective cyclopropanation, and methods of cyclopropanation are provided. The chiral ruthenium catalyst is prepared in situ by combining an alkenyl ligand, a deprotonated chiral salen ligand, and a ruthenium (II) metal. A preferred catalyst is prepared in situ by combining 2,3-dihydro-4-venylbenzofuran, deprotonated 1,2-cyclohexanediamino-N,N'-bis(3,5-di-t-butyl-salicylidene) and RuCl(p-cymene)].

Ruthenium(II) catalysts for use in stereoselective cyclopropanations

Growing community of inventors

Apex, NC, United States of America

David Eugene Pereira